Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 5.80 billion. The enterprise value is 6.28 billion.
Market Cap | 5.80B |
Enterprise Value | 6.28B |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
Earnings Date | Nov 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 223.04 million shares outstanding. The number of shares has increased by 8.79% in one year.
Shares Outstanding | 223.04M |
Shares Change (YoY) | +8.79% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 1.28% |
Owned by Institutions (%) | n/a |
Float | 37.31M |
Valuation Ratios
The trailing PE ratio is 48.69.
PE Ratio | 48.69 |
Forward PE | n/a |
PS Ratio | 5.44 |
PB Ratio | 3.27 |
P/FCF Ratio | 39.96 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.46, with an EV/FCF ratio of 43.28.
EV / Earnings | 52.73 |
EV / Sales | 5.89 |
EV / EBITDA | 22.46 |
EV / EBIT | 43.61 |
EV / FCF | 43.28 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 37.36.
Current Ratio | 1.32 |
Quick Ratio | 0.71 |
Debt / Equity | 37.36 |
Debt / EBITDA | 2.37 |
Debt / FCF | 4.56 |
Interest Coverage | 10.07 |
Financial Efficiency
Return on equity (ROE) is 6.97% and return on invested capital (ROIC) is 3.74%.
Return on Equity (ROE) | 6.97% |
Return on Assets (ROA) | 3.48% |
Return on Capital (ROIC) | 3.74% |
Revenue Per Employee | 6.16M |
Profits Per Employee | 688,416 |
Employee Count | 173 |
Asset Turnover | 0.41 |
Inventory Turnover | 2.03 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.33% in the last 52 weeks. The beta is 0.17, so Orient Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.17 |
52-Week Price Change | +30.33% |
50-Day Moving Average | 27.10 |
200-Day Moving Average | 23.75 |
Relative Strength Index (RSI) | 35.72 |
Average Volume (20 Days) | 34,791 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.07 billion and earned 119.10 million in profits. Earnings per share was 0.53.
Revenue | 1.07B |
Gross Profit | 585.21M |
Operating Income | 144.02M |
Pretax Income | 151.31M |
Net Income | 119.10M |
EBITDA | 260.01M |
EBIT | 144.02M |
Earnings Per Share (EPS) | 0.53 |
Balance Sheet
The company has 180.54 million in cash and 661.70 million in debt, giving a net cash position of -481.16 million or -2.16 per share.
Cash & Cash Equivalents | 180.54M |
Total Debt | 661.70M |
Net Cash | -481.16M |
Net Cash Per Share | -2.16 |
Equity (Book Value) | 1.77B |
Book Value Per Share | 7.94 |
Working Capital | 178.50M |
Cash Flow
In the last 12 months, operating cash flow was 170.73 million and capital expenditures -25.61 million, giving a free cash flow of 145.12 million.
Operating Cash Flow | 170.73M |
Capital Expenditures | -25.61M |
Free Cash Flow | 145.12M |
FCF Per Share | 0.65 |
Margins
Gross margin is 54.92%, with operating and profit margins of 13.51% and 11.18%.
Gross Margin | 54.92% |
Operating Margin | 13.51% |
Pretax Margin | 14.20% |
Profit Margin | 11.18% |
EBITDA Margin | 24.40% |
EBIT Margin | 13.51% |
FCF Margin | 13.62% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -8.79% |
Shareholder Yield | -8.79% |
Earnings Yield | 2.05% |
FCF Yield | 2.50% |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
Last Split Date | May 23, 2016 |
Split Type | Reverse |
Split Ratio | 0.6500936135 |